BioPharma « Terug naar discussie overzicht

GNBT - Generex Biotechnology - Deel 3

703 Posts, Pagina: « 1 2 3 4 5 6 ... 26 27 28 29 30 31 32 33 34 35 36 » | Laatste

Omlaag ↓

svenhedin 18 oktober 2010 16:11

En dan deze nog.... (Yahoo-forum)

This just out.

36 minutes agoPR Newswire

WORCESTER, Mass., Oct. 18 /PRNewswire-FirstCall/ -- Generex Biotechnology Corporation (Nasdaq: GNBT, www.generex.com) announced today that Dr. Joseph Rubinfeld, an independent scientific advisor to the Company and a member of the Company's Scientific Advisory Board, issued the following statement in respect of the reverse stock split proposal being considered at today's special meeting of the Generex stockholders:

"Having been intimately involved in the drug development world for over 40 years, I have hands-on experience with the dilemma faced by Generex and its shareholders on the day of this important vote. Many shareholders have personal experience with a reverse split or a delisting which has helped to shape their opinion on how to vote. Still others may look to point the finger of blame at management regardless of the current management's role in arriving at this point. I believe that it is important for every shareholder at this time to carefully consider the future in casting their vote as opposed to looking in the rear view mirror. I myself am confident that Generex has the ability to become a powerful force in immunotherapeutic vaccines and delivery of metabolic drug therapies but, there is still work ahead. That work includes further clinical trials and, in time, collaboration with larger pharmaceutical companies. As we continue to do this work we will look to the capital markets and there is no doubt that our financing opportunities will be more advantageous to our current shareholder base as a NASDAQ listed company. The same holds true when negotiating with potential partners. Generex stock is at a crossroads and I believe that approving the reverse split proposal is at this time in the best interest for the company and its stockholders as in the long term it will place the company on a more solid footing and result in much less overall dilution. I urge all who have not voted or have voted against the proposal to support Mark Fletcher and vote Yes.

svenhedin 18 oktober 2010 21:22

Generex Reschedules Live Video Webcast

WORCESTER, Mass., Oct 18, 2010 /PRNewswire via COMTEX/ -- Generex Biotechnology Corporation (GNBT) () announced today that its live video webcast from the NASDAQ Marketsite, originally scheduled for Tuesday, October 19, 2010, has been rescheduled to Thursday, October 21, 2010 as a result of the adjournment of the Special Meeting of the Company's Stockholders to this afternoon.

[verwijderd] 20 oktober 2010 00:17

Het verdict van GNBT is gevallen.Vanaf 21 oktober noteren ze onder dezelfde ticker GNBT op de Otcb markt. De koers is nabeurs met -19.82% gezakt tot 0.29

------------------------------------------------------------------------------------------------------------------------------------------------------

Generex Common Stock to be Quoted on the OTCQB Under the Symbol 'GNBT' Beginning Thursday, October 21, 2010

2010-10-19 16:39 ET - News Release

Common Stock will no longer be traded on the NASDAQ Capital Market beginning on that date
Generex Will Continue to Pursue its Product Development & Commercialization Initiatives Unabated

WORCESTER, Mass., Oct. 19 /PRNewswire-FirstCall/ -- Generex Biotechnology Corporation (www.generex.com) announced today that on October 19, 2010 the NASDAQ Listing Qualifications Panel notified the Company that the Panel has determined to delist the Company's common stock from the NASDAQ Capital Market and will suspend trading of the stock effective at the open of trading on Thursday, October 21, 2010 as a consequence of the Company's non-compliance with NASDAQ's minimum $1.00 per share closing bid price requirement.

The Company has been advised by Pink OTC Markets Inc., which operates an electronic quotation service for securities traded over-the-counter (OTC), that the Company's common stock is immediately eligible for quotation on the OTCQB effective with the opening of the markets on October 21, 2010. The OTCQB is a market tier for OTC traded companies that are registered and reporting with the Securities and Exchange Commission. The Company has also been advised that its common stock will continue to trade under the symbol "GNBT". Investors will be able to view real time stock quotes for GNBT at www.otcmarkets.com.

In September, 2010, there were 3,871 securities quoted on the OTCQB and the aggregate dollar value traded was just under $4 billion.

Generex management and its Board of Directors remain fully committed to the aggressive pursuit of the Company's product development and commercialization initiatives. "The move to the OTCQB is not reflective of the value and tremendous potential of our pipeline," said Mark Fletcher, the Generex Interim President & Chief Executive Officer. "Our efforts to move our pipeline products forward to commercialization will continue unabated."

At the reconvened Special Meeting of the Company's stockholders held on October 18, 2010, the reverse stock split proposal put forward by the Company's Board of Directors as a means of maintaining the Company's NASDAQ listing did not achieve the necessary vote in time for the meeting.

Of the 269,360,643 shares outstanding as of the August 12 record date, 191,872,323 shares (71.24%) were voted. The 127,819,048 shares voted in favor of the proposal represented 66.61% of votes cast and 47.45% of the outstanding shares. Approval of the proposal required a majority of the outstanding shares to vote in favor; accordingly, the vote fell 2.56% short.

During the week following the Company's October 11th announcement of its pending acquisition of a 51% equity interest in Global Medical Direct, LLC, interest in the reverse stock split proposal increased dramatically. During that period, the number of shares voted in favor of the proposal increased by 42,312,013 (an increase of nearly 50%) and the number of shares voted against the proposal decreased by 29,497,077 (a decrease of almost 32%) and the number of shares voted overall increased by 11,749,664 (a 13% increase).

In light of the increased stockholder support for the reverse stock split proposal as evidenced by the voting pattern over the past week, the Company will appeal the Panel's delisting determination to the NASDAQ Listing and Hearing Review Council. The Listing Council is a standing independent advisory committee appointed by NASDAQ's Board of Directors that, among other things, hears appeals of Panel decisions to delist. The suspension of the Company's common stock from trading on NASDAQ will remain in place throughout the appeal process, although the stock will be quoted on the OTCQB during that time.

www.stockwatch.com/News/Item.aspx?bid...

Skip

svenhedin 20 oktober 2010 12:08

Begrijp ik goed dat er vandaag voor het laatst nog via de Nasdaq kan worden gehandeld ??
Goed aankoopmoment ??

svenhedin 20 oktober 2010 15:51

quote:
svenhedin schreef:
Begrijp ik goed dat er vandaag voor het laatst nog via de Nasdaq kan worden gehandeld ??
Goed aankoopmoment ??

Gisteren 7500 verkocht voor 0,365
Vandaag toch maar teruggekocht voor 0,275
Kan toch geen bodemloze put zijn dit bedrijf !

Wat doen jullie forumbezoekers ?
Laat eens iets horen.

[verwijderd] 20 oktober 2010 17:17

Heb ook wat bijgekocht op 0,296. De tijd zal het leren, maar ik kan me niet voorstellen dat ze met al die patenten e.d. niet een keer wat substantieels gaan doen.. Voorlopig laat ik ze dus een jaar of wat op de plank liggen.

svenhedin 20 oktober 2010 17:24

Deze bijdrage (bron Yahoo forum) is wel aardig in dit verband.

Guess who is exploiting these markets at lightspeed?

www.marketsandmarkets.com/Market-...

Billion$ being spent/invested by PFE and the market will NOT sell them off...hmmmmmm!

P F I Z E R(PFE) spending money like a drunken sailor, buying up pharmas in INDIA and BRAZIL just announced....to grow in those Diabetes care markets...don't be surprised to hear soon they drop a couple million on GNBT, which immediately recapitalizes GNBT, repeal won, back on NASDAQ, and PFE partners Oral-Lyn but ultimately they want AE37 and will advance the clinical trials of that drug for a piece of the market!

If not PFE than Sanofi-Adventis who supplys their Insulin!

But I'm just saying!

Frank

Sentiment : Strong Buy

orchid 20 oktober 2010 19:15

Ik ben nu erg kritisch geworden na de vele uistellen en slechte PR 's. ze hebben geen controle over processen.
Ben er uit gestapt op 57 ct maar wil weer intappen, ik geloof in de pipeline heb alleen grote moeite met het slechte management.
Vandaag onder de 30 cent, denk dat ze daar wel even onderblijven, misschien nu eens een echte PR morgen., maar tot nu toe alleen teleurstellingen met dit bedrijf.
Kortom ik ben erg kritisch door de vele tekortkomingen van de top, Oral lyn al 10 jaar in ontwikkeling waar staan we nu echt??
Waar betalen ze de overname van BSD van? ze hebben het geld niet, dus weer verwatering, of er moet plotseling een partner met investeringen opstaan.
De laatste
"partner"die aandelen met korting kocht, dumpte ze direct weer de markt, fijn management, alles over de rug van de aandeelhouder.

Ik volg het stap weer in..alleen wanneer..

svenhedin 21 oktober 2010 15:37

Niet meer te volgen op Nasdaq quote.

Koersen te volgen op : www.finance-yahoo.com + GNBT.PK (vertraagd)

svenhedin 21 oktober 2010 15:59

quote:
svenhedin schreef:
Niet meer te volgen op Nasdaq quote.

Koersen te volgen op : www.finance-yahoo.com + GNBT.PK (vertraagd)

Herstel: Info Quotes op Nasdaq quote werkt nog wel.
(geen Premarket/Aftermarket m.i.)

Prima opening met hoog volume ! (0,349 high)

svenhedin 21 oktober 2010 16:04

Nog een gevolg (zoals mocht worden verwacht).
Bij Alex uitsluitend verkooporders via internet;
kooporders per telefoon. BALEN!!!!!

svenhedin 21 oktober 2010 16:17

De mooiste site om te volgen is wellicht: www.otcmarkets.com
Succes.

orchid 21 oktober 2010 17:21

ze hebben geld nodig, dus wat denk je dat de koers zal gaan doen??

[verwijderd] 28 oktober 2010 16:43

wEINIG BELANGSTELLING MEER SINDS OTC

gustaaf1e 28 oktober 2010 19:24

quote:
Peermanpaapskop schreef:
wEINIG BELANGSTELLING MEER SINDS OTC

Peer,
Qua handelsvolume vind ik dat nogal meevallen.
Als je bedoelt: op dit forum: ja, maar dat geldt voor het hele forum.
G

svenhedin 6 december 2010 22:27

NEWS - New Positive AE37 Phase II Breast Cancer Vaccine Data 6-Dec-10 08:13 am Generex Presents New Positive AE37 Phase II Breast Cancer Vaccine Data

WORCESTER, Mass., Dec. 6, 2010 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTC Bulletin Board: GNBT) today announced two presentations of data obtained from its on-going Phase II trial of its novel immunotherapeutic AE37 vaccine in breast cancer patients. The presentations, entitled Combination Immunotherapy: Safety and Immunologic Data from a Phase II Trial Administering a HER2/neu-derived Peptide Vaccine Sequentially or Concurrently with Trastuzumab and Increased prevalence of HLA-DR3 among breast cancer patients: implications for adjuvant HER2/neu peptide vaccine trials, will be made at the 33rd Annual San Antonio Breast Cancer Symposium (www.sabcs.org) in San Antonio, Texas from December 8-12, 2010.

The presentation on combination immunotherapy reports that patients receiving both AE37 and Trastuzumab (Herceptin®), a monoclonal antibody targeting the same protein, have increased specific immune-stimulation of T cells when AE37 is given simultaneous to administration of Trastuzumab rather than following Trastuzumab treatment. These results confirm prior published reports suggesting that the combination of Trastuzumab with active immunotherapy can work synergistically in cancer patients.

The second presentation reports that patients who are genetically predisposed to less efficiently recognize peptides derived from the HER2 protein have an immunological response to the AE37 HER2 peptide vaccine that is similar in robustness to the response in patients not having this predisposition. This is promising confirmation that AE37, which is designed as a self-potentiating peptide vaccine, indeed has improved activity that may be clinically relevant.

The 2010 CTRC-AACR San Antonio Breast Cancer Symposium, an international scientific symposium for interaction and exchange among scientists and clinicians in breast cancer, is presented by Cancer Therapy & Research Center at UT Health Science Center San Antonio, the American Association for Cancer Research, and Baylor College of Medicine. The driving force behind this collaboration is the shared mission of the organizations to advance progress against breast cancer. By combining their respective strengths, the San Antonio Breast Cancer Symposium encompasses the full spectrum of breast cancer research and facilitates the rapid transition of new knowledge into improved care for breast cancer patients.

svenhedin 9 december 2010 19:39

Generex Names Former Eli Lilly Senior Medical Director Dr. James H. Anderson, Jr. to its Scientific Advisory Board

Will provide advice & assistance on the Company's clinical, regulatory, & commercialization efforts for Generex Oral-lyn™ & its diabetes pipeline

WORCESTER, Ma., Dec. 9, 2010 /PRNewswire-FirstCall/ -- Generex Biotechnology Corporation (www.generex.com) (OTC Bulletin Board:GNBT) today announced the appointment of Dr. James H. Anderson, Jr., MD, FFPM, FACE to the Company's Scientific Advisory Board. Dr. Anderson will bring his wealth of clinical, regulatory, and commercialization experience in the diabetes field to the SAB to assist Generex with the commercialization of its pipeline of diabetes products including Generex Oral-lyn™, the Company's proprietary buccal insulin spray product.

Commenting on the appointment, Dr. Anderson stated, "Having worked with the Generex team in the fledgling stage of Generex Oral-lyn™ development while at Eli Lilly, I believed then that the product had the potential to become a first-in-class therapeutic insulin treatment even though the companies ultimately headed in different directions as is often the case with early stage collaborations. Over the course of time I have watched Generex overcome a number of hurdles with Generex Oral-lyn™, poised to finally reach its potential in diabetes treatment. I am now privileged to become involved again as Generex Oral-lyn™ approaches the latter stages of the regulatory process en-route to commercialization. It will be a pleasure to come full-circle to finish the work with this important and innovative initiative with tremendous market potential."

Dr. Anderson, a former Lieutenant Colonel in the United States Army's Medical Corps, worked for Eli Lilly and Company from 1985 until 2009. From July 2006 to December 2009, Dr. Anderson served as Eli Lilly's Senior Medical Director, Diabetes and Cardio-metabolic Medicine. Dr. Anderson is presently a Clinical Associate Professor of Medicine in the Division of Endocrinology and Metabolism at Indiana University Medical School, a member of the American Diabetes Association's Community Leadership Board, and a member of the editorial boards of the peer-reviewed journals Diabetes, Technology and Therapeutics and Journal of Diabetes Science and Technology. Dr. Anderson is also an elected Fellow of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom and a Fellow of the American College of Endocrinology.

The Company believes that Generex Oral-lyn™ will offer a safe, simple, fast, effective, and pain-free alternative to prandial insulin injections which will improve patient compliance with therapeutic regimes thereby delaying the progress of diabetes and the onset of its myriad complications.

svenhedin 14 december 2010 17:47

Generex Announces Publication of New Positive Generex Oral-lyn Data in Peer-Reviewed Journal
Study data demonstrates effectiveness of buccal insulin spray in treating patients with impaired glucose tolerance

Press Release Source: Generex Biotechnology Corporation On Monday December 13, 2010, 7:30 am
WORCESTER, Mass., Dec. 13, 2010 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTC Bulletin Board:GNBT.ob - News) announced today that the peer-reviewed scientific journal Diabetes, Obesity and Metabolism has published new positive data in respect of Generex Oral-lyn™, the Company's proprietary buccal insulin spray product.

The paper, entitled Buccal spray insulin in subjects with impaired glucose tolerance: the prevoral study, appears in Volume 13, Issue 1 (January 2011) of the journal and is co-authored by a team from the Department of Endocrinology and Diabetes, University Campus Bio-Medico, Rome, Italy led by Professor Paolo Pozzilli and including: A. Palermo, N. Napoli, S. Manfrini, A. Lauria, and R. Strollo.

People affected by impaired glucose tolerance (IGT) represent more than 20% of the world's population and the prevalence of the condition is growing. Approximately one-third of people with IGT develop clinical type 2 diabetes mellitus within three to five years of an IGT diagnosis. More significantly, an increased risk for cardiovascular disease has been observed in IGT patients, even where type 2 diabetes does not develop. Although diet and exercise (the treatment for IGT suggested by current American Diabetes Association guidelines) delay the onset of type 2 diabetes, long-term prospects are poor.

Because a reduced first phase insulin response is a key factor in diagnosing IGT, the use of insulin therapy to reduce post-prandial glucose levels could be a targeted treatment for IGT. However, insulin therapy via subcutaneous injection is often rejected by patients and its use is generally limited to patients with type 2 diabetes where oral hypoglycaemic options have failed.

....... Read all the PR on GNBT

As a result of these important findings, a second trial (Prevoral 2) is underway where subjects with IGT are being treated for six months with either (a) Generex Oral-lyn™ + diet and exercise, or (b) the standard IGT treatment of only diet and exercise. The end-point of the Prevoral 2 study is represented by glycated haemoglobin values. Initial promising data were presented in September at the 46th Congress of the European Association of the Study of Diabetes in Stockholm, Sweden. Final results of the Prevoral 2 study will be available in mid-2011.

svenhedin 14 december 2010 17:53

Zou toch mooi zijn na jaren van ellende hier.
Wie volgt dit aandeel nog ??

From Yahoo:
More and more good news for Oral Lyn and AE37 will come out soon. GNBT will back up, look for target $6 as analyst belived.

DNDN was traded ~$1 year ago, now it is above $40!

gustaaf1e 2 januari 2011 17:23

Ik volg dit aandeel alweer enige tijd.
Zonder in details te treden (kijk eens rustig op hun site naar pipeline, financiële positie, te verwachten inkomsten komende tijd en op wat langere termijn, komende events, concurrentiepositie e.d.): lijkt me wel een aandeel om iets meer mee te doen dan alleen volgen.
G

703 Posts, Pagina: « 1 2 3 4 5 6 ... 26 27 28 29 30 31 32 33 34 35 36 » | Laatste

Aantal posts per pagina: 20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Markt vandaag

AEX 903,61 -1,97 -0,22% 31 mei


Germany40^	18.585,90	+0,48%
BEL 20	3.918,09	+0,24%
EURO50	5.011,20	0,00%
US30^	38.701,80	0,00%
Nasd100^	18.538,90	0,00%
US500^	5.280,42	0,00%
Japan225^	38.630,50	0,00%
Gold spot	2.327,41	0,00%
EUR/USD	1,0834	0,00%
WTI	77,14	0,00%